2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patterns
2022
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
Sands J, Reck M, Navarro A, Chiang A, Lu S, Peled N, Paz-Ares L, Kerr S, Takahashi T, Smolin A, Chen X, Zhao B, El-Osta H, Califano R. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. Journal Of Clinical Oncology 2022, 40: tps8606-tps8606. DOI: 10.1200/jco.2022.40.16_suppl.tps8606.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerEtoposide/platinumPatient-reported outcomesSmall cell lung cancerPhase 3 studyLung cancerRECIST v1.1ECOG PSDisease progressionBlinded independent central reviewNeurologic paraneoplastic syndromesUntreated ES-SCLCFirst-line pembrolizumabFirst-line treatmentInterstitial lung diseaseCell lung cancerDuration of responseT cell immunoreceptorIndependent central reviewWithdrawal of consentPretreatment tumor samplesNew anticancer treatmentsCare immunotherapyCTCAE v5.0Measurable disease
2020
Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.
Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerFirst-line chemoSmall cell lung cancerES-SCLC patientsCell lung cancerSurvival benefitIO patientsLung cancerStudy periodFirst-line atezolizumabInitial systemic therapyProphylactic cranial irradiationFirst-line chemotherapyRetrospective cohort analysisContemporary practice patternsDe-identified databaseUse of PCIEffectiveness of PCICHEMO patientsCranial irradiationIO therapyPCI useSystemic therapyMRI surveillancePractice patternsA multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.
Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.Peer-Reviewed Original ResearchCell lung cancerLung cancerOverall survivalOutcome dataExtensive-stage small-cell lung cancerMetastatic non-small cell lung cancerNon-small cell lung cancerSmall cell lung cancerReal-world clinical outcomesGenomic profilingFirst tumor assessmentFlatiron Health networkTechnology-enabled abstractionLines of therapyMetastatic lung cancerEnd of treatmentWithdrawal of consentClinical data pointsEnd of studyTumor DNA ProfilingAnti-neoplastic treatmentCase report formsTumor tissue samplesBlood genomic profilingElectronic health records
2017
1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, Faoro L, Chiang A. 1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals Of Oncology 2017, 28: v540. DOI: 10.1093/annonc/mdx386.004.Peer-Reviewed Original ResearchUntreated extensive stage small cell lung cancerExtensive-stage small-cell lung cancerSmall cell lung cancerPhase 2 studyLung cancerTarextumabPatientsCancerEtoposide
2016
1425PD Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
Sequist L, Chiang A, Gilbert J, Gordon M, Conkling P, Thompson D, Marcoux J, Antonia S, Liu B, Shames D, Lopez-Chavez A, O'Hear C, Fasso M, Gettinger S. 1425PD Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Annals Of Oncology 2016, 27: vi493. DOI: 10.1093/annonc/mdw389.03.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerSmall cell lung cancerCell lung cancerLung cancerClinical activityBiomarker resultsCancerTrialsUpdated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Chiang A, Rudin C, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Liu S, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2016, 34: 8564-8564. DOI: 10.1200/jco.2016.34.15_suppl.8564.Peer-Reviewed Original ResearchUntreated extensive stage small cell lung cancerExtensive-stage small-cell lung cancerSmall cell lung cancerPhase 1b studyLung cancerTarextumabPatientsCancerEtoposideCarfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.
Badin F, Chiang A, Fisher W, Orlov S, Harper H, Eskander E, Harb W, Kio E, Gopalan P, Haggstrom D, Burdaeva O, Zahlten-Kumeli A, Aggarwal S, Obreja M, Gorbunova V. Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study. Journal Of Clinical Oncology 2016, 34: e20092-e20092. DOI: 10.1200/jco.2016.34.15_suppl.e20092.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerUntreated extensive stage small cell lung cancerSmall cell lung cancerPhase 1b/2 studyCell lung cancer
2015
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Chiang A, Liu S, Kapoun A, Xu L, Hill D, Dupont J, Spigel D, Zhou L. Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2015, 33: 7508-7508. DOI: 10.1200/jco.2015.33.15_suppl.7508.Peer-Reviewed Original ResearchUntreated extensive stage small cell lung cancerExtensive-stage small-cell lung cancerSmall cell lung cancerLung cancerPhase IbTarextumabPatientsCancerEtoposide
2014
1473P Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle Study
Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Liu S, Gluck W, Kalemkerian G, Chiang A, Hart L, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. 1473P Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle Study. Annals Of Oncology 2014, 25: iv514. DOI: 10.1093/annonc/mdu355.11.Peer-Reviewed Original ResearchDose-limiting toxicityAnti-tumor activityDay 1Untreated extensive stage small cell lung cancerExtensive-stage small-cell lung cancerMain dose-limiting toxicitySmall cell lung cancerGrade 3 diarrheaGrade 3 nauseaPhase 2 partPhase 1b trialPK/pharmacodynamicsED-SCLCSCLC xenograftsDose cohortsRECIST 1.1Peripheral edemaUnacceptable toxicityAdverse eventsSupportive carePreliminary efficacyLung cancerDisease progressionEfficacy dataIgG2 antibodies